← Back to Search

Statin

EMERALD protocol for Lipid Disorders (EMERALD Trial)

Phase 4

Waitlist Available

Led By Simon Mahler, MD

Research Sponsored by Wake Forest University Health Sciences

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline and day 30

Awards & highlights

EMERALD Trial Summary

This trial tested a cholesterol-management strategy in the ER to reduce long-term heart risk. It prescribed statins and referred patients to outpatient care.

Eligible Conditions

Lipid Disorders

EMERALD Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline and day 30

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline and day 30

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and day 30 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Low-density Lipoprotein Cholesterol (LDL-C) Levels at Baseline and Day 30

Secondary outcome measures

Change in non-high-density lipoprotein cholesterol (non-HDL-C) levels

EMERALD Trial Design

1Treatment groups

Experimental Treatment

Group I: EMERALD protocolExperimental Treatment1 Intervention

1) ordering a lipid panel during the index ED encounter and 30-days (+/- 5 business days) after ED discharge, 2) completion of the Pooled Cohort Equations by the patient's ED provider at the index visit, and 3) starting medical therapy (moderate- or high-intensity statin/ rosuvastatin) in the ED

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

moderate- or high-intensity statin/ rosuvastatin

2023

Completed Phase 4

~30

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Wake Forest University Health SciencesLead Sponsor

1,239 Previous Clinical Trials

1,004,161 Total Patients Enrolled

Simon Mahler, MDPrincipal InvestigatorWake Forest University Health Sciences

3 Previous Clinical Trials

1,081 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who is eligible to enroll in this research project?

"This trial is looking for up to 20 participants between the ages of 40 and 75 with a pre-existing lipid disorder."

Answered by AI

Has the EMERALD protocol been sanctioned by the FDA?

"Due to being in Phase 4 of the trial, EMERALD protocol was given a score of 3 on our safety scale. This indicates that this treatment has been approved for use by regulatory bodies."

Answered by AI

Is this research endeavor accessible to those below the age of seventy?

"This study calls for participants aged 40 to 75. For those under 18 years old, there are 43 trials and 175 clinical studies available for people older than 65."

Answered by AI

Is it currently feasible to apply for this clinical trial?

"The evidence on clinicaltrials.gov indicates that this particular medical trial is not presently enrolling patients, although it was initially posted on March 1st 2023 and last edited February 15th 2023. Nonetheless, there are 215 other studies actively seeking participants as of now."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)

2023. "EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05742841.